Synapsoft logo
AI Insights from Disclosures
Searching...
KWANGDONG PHARMACEUTICAL CO.,LTD 009290
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
KWANGDONG PHARMACEUTICAL CO.,LTD divides its sales segments into the pharmacy sales segment (OTC), the hospital sales segment (ETC), and the F&B sales segment. By segment, the main products and revenue (share) were as follows: the pharmacy segment, including Chongshimwon products at KRW 30.1 billion, among others, totaled KRW 90.8 billion (18.7%); the hospital segment, including vaccines, anti-cancer drugs, and other prescription drugs, totaled KRW 110.2 billion (22.6%); and the F&B segment, including Jeju Samdasoo at KRW 156.7 billion, Vita500 at KRW 46.3 billion, corn silk tea at KRW 19.8 billion, and Hutgae tea at KRW 20.8 billion, among others, totaled KRW 266.0 billion (54.6%); first-half 2024 revenue reached KRW 486.9 billion.
Representative Director 최성원, 박상영(각자대표)
Founded October 16, 1963
Corporation Type KOSPI
Industry Classification Manufacture of herb medicaments
Corporate number 11011-0152134
Business number 113-81-08888
Phone Number 02-6006-7777
Fax Number 02-6006-7021
Website www.ekdp.com
Company Address 52 Gwacheon-daero 7da-gil, Gwacheon-si, Gyeonggi-do
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant